# A Clinical Trial With KJ103 in Anti-GBM Disease

> **NCT06607016** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Bao Pharmaceuticals Co., Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- Anti-Glomerular Basement Membrane Disease

## Interventions

- **DRUG:** KJ103 for Injection
- **DRUG:** Cyclophosphamide
- **DRUG:** Glucocorticoids
- **PROCEDURE:** Plasma exchange (PE)

## Key facts

- **NCT ID:** NCT06607016
- **Lead sponsor:** Shanghai Bao Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-21
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-03
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06607016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06607016, "A Clinical Trial With KJ103 in Anti-GBM Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06607016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*